MCT1 inhibitors (e.g., AZD3965) are currently undergoing Phase II trials for pancreatic and breast cancer, with the objective of obstructing lactate export and acidifying TME to rejuvenate T cell functionality. The gene discussed is SLC16A1; the disease is breast carcinoma.